Egg White Powder for High Blood Sugar and High Blood Pressure

Recruiting in Palo Alto (17 mi)

Overseen by Jianping Wu, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: University of Alberta

Trial Summary

What is the purpose of this trial?

Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure. Participants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week. Participants in the healthy control group will undergo 1 treatment only (one day).

Research Team

Jianping Wu, PhD

Principal Investigator

University of Alberta

Eligibility Criteria

This trial is for individuals at high risk of type 2 diabetes or those already diagnosed with it. They should be willing to consume a standardized breakfast with a smoothie containing different protein powders on four separate days, each one week apart. Healthy controls will participate in just one treatment.

Inclusion Criteria

I am between 18 and 70 years old and live near Edmonton.

Healthy control group: Triglycerides below 1.7 mmol/L

Individuals at risk of diabetes/having type 2 diabetes: Waist circumference at or above specific ethnic cut-offs

Exclusion Criteria

Smokers (current smokers: daily/occasional and those who have smoked more than 100 cigarettes in their life)

I regularly take anti-inflammatory drugs, such as aspirin, antihistamines, or omega-3 supplements.

Pregnant/lactating women

Treatment Details

Interventions

• IRW from Egg White Hydrolysate (Bioactive Peptide)

Trial Overview The study is testing the health effects of IRW, a bioactive peptide from egg white hydrolysate, on managing high blood sugar and pressure. Participants will receive this ingredient through smoothies during their breakfast to see if there's an acute benefit.

Participant Groups

Group I: Egg white hydrolysate Thermoase (5 g) (powder) Experimental Treatment 1 Intervention

5 g; dose based on human equivalent dose calculation; only individuals at risk of diabetes/having type 2 diabetes

Group II: Egg white hydrolysate Thermoase (20 g) (powder) Experimental Treatment 1 Intervention

20 g; dose based on energy percentage used in animal experiment; both healthy control group and at risk of diabetes/having type 2 diabetes

Group III: Egg white hydrolysate Thermoase + Pepsin (20 g) liberating IRW (powder) Active Control 1 Intervention

20 g; positive control, only individuals at risk of diabetes/having type 2 diabetes

Group IV: Egg white powder (20g) Placebo Group 1 Intervention

20 g of egg white powder from the market; negative control; only individuals at risk of diabetes/having type 2 diabetes.

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University of Alberta Edmonton, Canada

Who Is Running the Clinical Trial?

University of Alberta

Lead Sponsor

Trials

957

Recruited

437,000+

Bill Flanagan

University of Alberta

Chief Executive Officer since 2020

LLB from University of Toronto, LLM from Columbia University

Dr. Verna Yiu

University of Alberta

Chief Medical Officer since 2012

MD from University of Alberta, Fellowship in Pediatric Nephrology at Harvard University